Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fixed Schedule Clear all
Completed Phase 4 Interventional Results available

A Study of Sertraline to Prevent PTSD

NCT00182078
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression
Interventions
Placebo, Sertraline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 20 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TechStep: Technology-based Stepped Care to Stem Transgender Adolescent Risk Transmission

NCT04000724
View directory record Official record
Conditions
HIV
Interventions
Text Messaging (Text+Step), WebApp (App+Step), Information/No Step
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 24 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Take Charge of Your Diabetes

NCT01977495
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Financial Incentive: Fixed Lottery
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 14, 2026, 10:16 PM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 14, 2026, 10:16 PM EDT
Withdrawn Phase 2 Interventional

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

NCT05216614
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Parosmia
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Early Phase 1 Interventional

Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)

NCT00763178
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 4 Interventional

Treatment of Alcohol Withdrawal in Hospital Patients

NCT00249366
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
Lorazepam (drug), Lorazepam
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

NCT03264066
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib, Atezolizumab, Atezolizumab Cohort 7
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Contingency Management in Waterpipe Smoking Cessation

NCT02159092
View directory record Official record
Conditions
Waterpipe Smoking
Interventions
Contingency Management
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus

NCT01080326
View directory record Official record
Conditions
Peptic Ulcer
Interventions
Endoscopic Translumenal Omental Patch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 14, 2026, 10:16 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 14, 2026, 10:16 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

NCT04642365
View directory record Official record
Conditions
Solid Tumors
Interventions
RO7296682, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma

NCT03572530
View directory record Official record
Conditions
Recurrent Ependymoma
Interventions
5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional

Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy

NCT01086670
View directory record Official record
Conditions
Cerebral Palsy, Children, Adolescents
Interventions
Physical Exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
5 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 14, 2026, 10:16 PM EDT
Terminated No phase listed Observational

A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients

NCT00598936
View directory record Official record
Conditions
Coronary Artery Disease, Heart Valve Disease
Interventions
CDI 1000 COM and INVOS 5100
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome

NCT02036853
View directory record Official record
Conditions
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Interventions
Triheptanoin
Drug
Lead sponsor
Adrian Lacy
Other
Eligibility
1 Year to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 14, 2026, 10:16 PM EDT
Not listed Not applicable Interventional

Parent Led Implementation of a VR Social Skills Training Program for Children With ASD

NCT06098768
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
VR Social Skills
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
4 Years to 131 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 14, 2026, 10:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate
Drug · Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

ARemind: A Personalized System to Remind for Adherence

NCT01229722
View directory record Official record
Conditions
Medication Adherence
Interventions
Beeper, ARemind
Device
Lead sponsor
Dimagi Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Prediabetes: A Family-Centered Whole Foods Diet in Adults With Prediabetes and Their Offspring

NCT05483972
View directory record Official record
Conditions
PreDiabetes
Interventions
Whole Prediabetes Diet Intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
25 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 14, 2026, 10:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
STX-241
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 14, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Results available

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

NCT03512210
View directory record Official record
Conditions
Hepatitis C, HIV-1-infection, Liver Diseases
Interventions
Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
Drug · Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 14, 2026, 10:16 PM EDT